Association between patient ethnicity and prostate cancer diagnosis following a prostate-specific antigen test: a cohort study of 730,000 men in primary care in the UK

被引:10
作者
Down, Liz [1 ]
Barlow, Melissa [1 ]
Bailey, Sarah E. R. [1 ]
Mounce, Luke T. A. [1 ]
Merriel, Samuel W. D. [2 ]
Watson, Jessica [3 ]
Martins, Tanimola [1 ]
机构
[1] Univ Exeter, Dept Hlth & Community Sci, St Lukes Campus,Heavitree Rd, Exeter EX1 2LU, England
[2] Univ Manchester, Ctr Primary Care & Hlth Serv Res, Oxford Rd, Manchester M13 9PL, England
[3] Univ Bristol, Ctr Acad Primary Care CAPC, Bristol Med Sch, Populat Hlth Sci, 39 Whatley Rd, Bristol BS8 2PS, England
关键词
Ethnicity; Prostate-specific antigen; Prostate cancer; Blood tests; Health inequities; RACE; AGE;
D O I
10.1186/s12916-024-03283-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundBlack men have higher prostate-specific antigen (PSA) levels and higher prostate cancer incidence and mortality than White men, while Asian men tend to have lower prostate cancer incidence and mortality than White men. Much of the evidence comes from the USA, and information from UK populations is limited.MethodsThis retrospective cohort study used data on patients registered at general practices in England contributing to the Clinical Practice Research Datalink (CPRD) Aurum dataset. Those eligible were men aged 40 and over with a record of ethnicity and a PSA test result recorded between 2010 and 2017 with no prior cancer diagnosis.The aim was to assess the incidence of prostate cancer following a raised PSA test result in men from different ethnic groups. Additionally, incidence of advanced prostate cancer was investigated. Cancer incidence was estimated from multi-level logistic regression models adjusting for potential confounding factors.MethodsThis retrospective cohort study used data on patients registered at general practices in England contributing to the Clinical Practice Research Datalink (CPRD) Aurum dataset. Those eligible were men aged 40 and over with a record of ethnicity and a PSA test result recorded between 2010 and 2017 with no prior cancer diagnosis.The aim was to assess the incidence of prostate cancer following a raised PSA test result in men from different ethnic groups. Additionally, incidence of advanced prostate cancer was investigated. Cancer incidence was estimated from multi-level logistic regression models adjusting for potential confounding factors.Results730,515 men with a PSA test were included (88.9% White). Black men and men with mixed ethnicity had higher PSA values, particularly for those aged above 60 years. In the year following a raised PSA result (using age-specific thresholds), Black men had the highest prostate cancer incidence at 24.7% (95% CI 23.3%, 26.2%); Asian men had the lowest at 13.4% (12.2%, 14.7%); incidence for White men was 19.8% (19.4%, 20.2%). The peak incidence of prostate cancer for all groups was in men aged 70-79. Incidence of prostate cancer diagnosed at an advanced stage was similar between Black and White men.ConclusionsMore prostate cancer was diagnosed in Black men with a raised PSA result, but rates of advanced prostate cancer were not higher in this group. In this large primary care-based cohort, the incidence of prostate cancer in men with elevated PSA levels increases with increasing age, even when using age-adjusted thresholds, with Black men significantly more likely to be diagnosed compared to White or Asian men. The incidence of advanced stage prostate cancer at diagnosis was similar for Black and White men with a raised PSA result, but lower for Asian men.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Percent free prostate-specific antigen does not improve the effectiveness of prostate cancer detection in Chinese men with a prostate-specific antigen of 2.5-20.0 ng/ml: a multicenter study
    Huang, Maping
    Lin, Yurong
    Xu, Abai
    Uhlman, Matthew
    Deng, Xiangrong
    Lin, Xuanting
    Wu, Sifeng
    Diao, Pengfei
    Xie, Keji
    Tang, Ping
    MEDICAL ONCOLOGY, 2014, 31 (04)
  • [22] Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017
    Clift, Ashley Kieran
    Coupland, Carol A. C.
    Hippisley-Cox, Julia
    BRITISH JOURNAL OF GENERAL PRACTICE, 2021, 71 (703) : E157 - E165
  • [23] PROSTATE-SPECIFIC ANTIGEN TEST - OPERATING CHARACTERISTICS AND ASSESSMENT CRITERIA IN THE DIAGNOSIS OF PROSTATIC-CANCER
    PERIMENIS, P
    MARKOU, SA
    BARBALIAS, G
    UROLOGIA INTERNATIONALIS, 1992, 48 (02) : 171 - 174
  • [24] Is Prostate-Specific Antigen Surveillance Necessary in Men with Benign Prostate Pathology following Radical Cystoprostatectomy for Bladder Cancer?
    Bivalacqua, Trinity J.
    Loeb, Stacy
    Pierorazio, Phillip M.
    Schoenberg, Mark P.
    Partin, Alan W.
    Guzzo, Thomas J.
    UROLOGIA INTERNATIONALIS, 2010, 85 (04) : 466 - 469
  • [25] Seminal plasma microRNAs improve diagnosis/prognosis of prostate cancer in men with moderately altered prostate-specific antigen
    Barcelo, Maria
    Castells, Manel
    Perez-Riba, Merce
    Bassas, Lluis
    Vigues, Francesc
    Larriba, Sara
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2020, 12 (05): : 2041 - 2051
  • [26] A multicenter study on the detection of prostate cancer by digital rectal examination and prostate-specific antigen in men with or without urinary symptoms
    Gil, MJ
    Allepuz, C
    Rioja, LA
    Servet, HM
    Filella, X
    Molina, R
    Ballesta, AM
    Tallada, M
    Cozar, JM
    delasNieves, HV
    Arruza, A
    Pertusa, C
    Cruces, H
    Flores, N
    Zubiaur, C
    Basurto, H
    Ballesteros, JJ
    Esperanza, H
    Jimenez, JF
    Sanz, S
    LaFe, H
    Gallego, J
    Mingol, VF
    Guajardo, J
    Alija, J
    deVilanova, HA
    Camacho, E
    Garcia, M
    Valme, H
    Saladie, JM
    Comet, J
    Pujol, HGTI
    Leiva, O
    Rodriguez, A
    Solsona, E
    Casanova, JL
    Concepcion, T
    Banares, F
    Chicharro, JA
    Burgos, R
    Gonzalez, M
    Gomez, F
    Canalejo, HJ
    Sebastian, JL
    Millan, JA
    delCamino, HV
    Carballido, J
    deHierro, HP
    Palazon, J
    Ortiz, B
    EUROPEAN UROLOGY, 1997, 32 (02) : 133 - 139
  • [27] Serum ribonuclease activity in the diagnosis of prostate cancer in men with serum prostate-specific antigen levels between 2.5 and 20 ng/mL
    Eskicorapci, SY
    Özkara, HA
    Önder, E
    Akdogan, B
    Erkan, I
    Ciliv, G
    Ozen, H
    CLINICAL BIOCHEMISTRY, 2006, 39 (04) : 363 - 366
  • [28] Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen c velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
    Teoh, Jeremy Y. C.
    Tsu, James H. L.
    Yuen, Steffi K. K.
    Chiu, Peter K. F.
    Chan, Samson Y. S.
    Wong, Ka-Wing
    Ho, Kwan-Lun
    Hou, Simon S. M.
    Ng, Chi-Fai
    Yiu, Ming-Kwong
    ASIAN JOURNAL OF ANDROLOGY, 2017, 19 (01) : 98 - 102
  • [29] Prostate-specific antigen (PSA) bounce following salvage radiotherapy to the prostate bed in a patient with prostate cancer post-prostatectomy
    Rowe, Michael
    Adamson, Ellis
    McGrane, John
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2020, 9 (04) : 217 - 220
  • [30] Prostate-specific antigen (PSA) bounce following salvage radiotherapy to the prostate bed in a patient with prostate cancer post-prostatectomy
    Michael Rowe
    Ellis Adamson
    John McGrane
    International Cancer Conference Journal, 2020, 9 : 217 - 220